Bayer: last-minute presentations at ESMO congress

(CercleFinance.com) - Bayer announced on Friday that it plans to present the results of several trials at the European Society for Medical Oncology (ESMO) congress starting next week in Barcelona, including last-minute data in prostate cancer.


These Phase III results are to cover the combination of Nubeqa (darolutamide) and anti-androgen therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Nubeqa is currently approved for this indication in the USA, but in combination with chemotherapy.

It is also approved for the treatment of non-metastatic castration-resistant prostate cancer (CRPC).

In the latter indication, Bayer says it is also planning a last-minute presentation of a Phase III trial of Xofigo (radium-223 chloride) in combination with enzalutamide, for which it is one of the main sponsors.

Xofigo is currently approved in the US for the treatment of patients with castration-resistant prostate cancer who have symptomatic bone metastases and no known visceral metastatic disease.

The German pharmaceutical company also plans to unveil the results of two studies on the efficacy of Vitravki in adult and pediatric patients with TRK fusion cancer.


Copyright (c) 2024 CercleFinance.com. All rights reserved.